SABCS Expert Commentary | Professor Wang Xin: ctDNA Clearance Predicts pCR in HER2-Positive Breast Cancer and Supports Precision De-escalation Strategies

SABCS Expert Commentary | Professor Wang Xin: ctDNA Clearance Predicts pCR in HER2-Positive Breast Cancer and Supports Precision De-escalation Strategies

2026.01.13
De-escalation therapy has become an important trend in the management of HER2-positive early breast cancer, yet accurately identifying patients who can safely omit chemotherapy remains a major challenge. At the 2025 San Antonio Breast Cancer Symposium (SABCS), the PHERGuide substudy innovatively incorporated circulating tumor DNA (ctDNA) monitoring into the neoadjuvant treatment framework. The study demonstrated that ctDNA clearance is strongly associated with pathological complete response (pCR), while baseline ctDNA positivity predicts poorer outcomes.
Academician Xu Zhang: Advancing Surgery and Systemic Therapy in Parallel—China’s Comprehensive Management of Urologic Cancers Moves to the Global Forefront

Academician Xu Zhang: Advancing Surgery and Systemic Therapy in Parallel—China’s Comprehensive Management of Urologic Cancers Moves to the Global Forefront

2026.01.12
The 9th West China Urologic Oncology Tianfu Academic Conference and the 11th Annual Academic Meeting on Urologic and Male Genitourinary Tumors of the Sichuan Anti-Cancer Association were recently held successfully in Chengdu, Sichuan. Centered on urologic and male genitourinary malignancies, the conference emphasized timeliness and diversity, combining a global perspective with Chinese clinical realities to build a high-level platform for academic exchange and innovation in urologic oncology. During the meeting, Oncology Frontier – Urology Frontier invited Academician Xu Zhang from The Third Medical Center, Chinese PLA General Hospital to share his insights on China’s distinctive achievements in minimally invasive surgery, recent advances in systemic therapy, and their clinical value.
Professor Brian Rini: From Transcriptomic Signatures to KIM-1—Breakthroughs in Precision Therapy for Renal Cell Carcinoma | 15th Shanghai Academic Conference on Urologic Oncology

Professor Brian Rini: From Transcriptomic Signatures to KIM-1—Breakthroughs in Precision Therapy for Renal Cell Carcinoma | 15th Shanghai Academic Conference on Urologic Oncology

2026.01.12
From VEGF-targeted agents to immune-based combinations and novel HIF-2α inhibitors, the expanding therapeutic arsenal for renal cell carcinoma (RCC) has significantly prolonged patient survival. At the same time, it has posed a more demanding challenge for clinicians: how to tailor the optimal treatment for each individual patient and truly achieve precision medicine.
Professor Stephen J. Freedland: The EMBARK Study Opens a New Chapter of Intensified Therapy for High-Risk BCR Prostate Cancer

Professor Stephen J. Freedland: The EMBARK Study Opens a New Chapter of Intensified Therapy for High-Risk BCR Prostate Cancer

2026.01.12
In the treatment pathway of prostate cancer, biochemical recurrence (BCR) represents a critical turning point. Especially for high-risk BCR patients with a short PSA doubling time, how to delay disease progression and improve overall survival (OS) has long been a major clinical concern. At the recent 15th Shanghai Urological Oncology Academic Conference, Oncology Frontier – UroStream invited Professor Stephen J. Freedland from Cedars-Sinai Medical Center to provide an in-depth interpretation of the EMBARK study, including its study rationale, clinical benefits, and individualized treatment strategies for high-risk BCR patients.